In breast cancer, a higher FOSL1 expression is often observed in the ER-negative tumors, i.e., the most aggressive and highly malignant breast carcinomas, such as HER2-positive [83] and triple-negative breast carcinomas (TNBC) [84]. Here, ERBB2 is linked to breast carcinoma.